Session Item

Pancreatic cancer is the third leading cause of cancer-related death in the United States, with a five-year overall survival of approximately 8%. The prognosis of advanced local pancreatic cancer is unfavorable despite progression in therapy. Highly conformal stereotactic body radiation (SBRT) is a developing alternative.

This research is to investigate feasibility and safety of Stereotactic Body Radiotherapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC)

For our single-institution retrospective study of patients with pancreatic cancer treated with SBRT between 2018 and 2020, we identified an improvement in clinical outcomes. The mean dosage was 55 Gy (with a range of 25-66 Gy) delivered in 5-12 doses. Toxicity, overall survival, and metastasis, as well as the presence of local progression and RECIST 1.1 response evaluation criteria in solid tumors, were all included in the endpoint criteria.

Twenty patients were treated, with a median follow-up of nine months. Patients who received SBRT had unresectable (55%), or borderline resectable (5 %) disease, medically inoperable (10%), or developed local recurrence following the Whipple procedure (30%).

The median follow-up was 9 months (range 3-18 months). The actuarial 1 year local control rate was 65 %. The 2-year OS rates was 25 %, . The 1-year freedom from progression was 45 % . Median time to progression was 8 months. Two patients (10%) experienced late gastrointestinal (GI) grade 3 events.

For treating pancreatic cancer, SBRT might be regarded a promising strategy that provides local control while being linked with a slightly higher risk of late GI toxicities.  It is a more convenient treatment regimen in a shorter overall treatment time while being better tolerated by patients.